MXPA05008126A - Inhibidores de girasa y uso de los mismos. - Google Patents

Inhibidores de girasa y uso de los mismos.

Info

Publication number
MXPA05008126A
MXPA05008126A MXPA05008126A MXPA05008126A MXPA05008126A MX PA05008126 A MXPA05008126 A MX PA05008126A MX PA05008126 A MXPA05008126 A MX PA05008126A MX PA05008126 A MXPA05008126 A MX PA05008126A MX PA05008126 A MXPA05008126 A MX PA05008126A
Authority
MX
Mexico
Prior art keywords
compounds
gyrase inhibitors
relates
present
gyrase
Prior art date
Application number
MXPA05008126A
Other languages
English (en)
Spanish (es)
Inventor
Joseph Drumm
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MXPA05008126A publication Critical patent/MXPA05008126A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MXPA05008126A 2003-01-31 2004-01-29 Inhibidores de girasa y uso de los mismos. MXPA05008126A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44391703P 2003-01-31 2003-01-31
PCT/US2004/002541 WO2005012292A1 (en) 2003-01-31 2004-01-29 Gyrase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
MXPA05008126A true MXPA05008126A (es) 2006-03-30

Family

ID=34115255

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008126A MXPA05008126A (es) 2003-01-31 2004-01-29 Inhibidores de girasa y uso de los mismos.

Country Status (24)

Country Link
US (3) US7495014B2 (OSRAM)
EP (1) EP1592686B1 (OSRAM)
JP (2) JP4691033B2 (OSRAM)
KR (1) KR20060056270A (OSRAM)
CN (1) CN100393714C (OSRAM)
AR (1) AR042956A1 (OSRAM)
AT (1) ATE435859T1 (OSRAM)
AU (1) AU2004261545B2 (OSRAM)
CA (1) CA2513463C (OSRAM)
CY (1) CY1109385T1 (OSRAM)
DE (1) DE602004021904D1 (OSRAM)
DK (1) DK1592686T3 (OSRAM)
ES (1) ES2327642T3 (OSRAM)
IL (1) IL169720A (OSRAM)
MX (1) MXPA05008126A (OSRAM)
MY (1) MY139124A (OSRAM)
NO (1) NO20053845L (OSRAM)
NZ (1) NZ541885A (OSRAM)
PT (1) PT1592686E (OSRAM)
RU (1) RU2350612C2 (OSRAM)
SI (1) SI1592686T1 (OSRAM)
TW (1) TWI334416B (OSRAM)
WO (1) WO2005012292A1 (OSRAM)
ZA (1) ZA200505773B (OSRAM)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04012628A (es) * 2002-06-13 2005-03-23 Patricia Olivershaffer DERIVADOS Y COMPUESTOS RELACIONADOS DEL áCIDO 2-UREIDO-6-HETEROARIL-3H-BENZOIMIDAZOL-4-CARBOXILICO COMO INHIBIDORES DE GIRASA Y/O TOPOISOMERASA IV PARA EL TRATAMIENTO DE INFECCIONES BACTERIALES.
US8404852B2 (en) 2003-01-31 2013-03-26 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7569591B2 (en) * 2003-01-31 2009-08-04 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US8193352B2 (en) 2003-01-31 2012-06-05 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7582641B2 (en) 2003-01-31 2009-09-01 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
US7618974B2 (en) 2003-01-31 2009-11-17 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7863335B2 (en) * 2004-07-23 2011-01-04 The University Of Medicine And Dentistry Of New Jersey Non-antibiotic intervention of chlamydial infection
MX2007014114A (es) 2005-05-10 2008-03-14 Intermune Inc Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
DE102005028862A1 (de) * 2005-06-22 2007-01-11 Sanofi-Aventis Deutschland Gmbh Substituierte Heterocyclen, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US8394803B2 (en) * 2005-11-07 2013-03-12 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US8481544B2 (en) 2006-06-22 2013-07-09 Biota Europe Limited Antibacterial compositions
GB0612428D0 (en) * 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
GB0724349D0 (en) * 2007-12-13 2008-01-30 Prolysis Ltd Antibacterial agents
WO2009001915A1 (ja) * 2007-06-28 2008-12-31 Takeda Pharmaceutical Company Limited 置換イミダゾール化合物およびその用途
WO2009027733A1 (en) * 2007-08-24 2009-03-05 Astrazeneca Ab (2-pyridin-3-ylimidazo[1,2-b]pyridazin-6-yl) urea derivatives as antibacterial agents
AU2008335409A1 (en) 2007-12-07 2009-06-18 Vertex Pharmaceuticals Incorporated Solid forms of 1-ethyl-3-(5-(5-fluoropyridin-3-yl)-7-(pyrimidin-2-yl)-1H-benzo[d] imidazol-2-yl)urea
GB0724342D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
PE20091268A1 (es) * 2007-12-19 2009-09-19 Amgen Inc Derivados heterociclicos como inhibidores de pi3 quinasa
TW200940537A (en) * 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
JP5627574B2 (ja) 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
MX2010013310A (es) 2008-06-04 2011-03-01 Astrazeneca Ab Derivados de heterociclil urea para el tratamiento de infecciones bacterianas.
US20110166088A1 (en) * 2008-06-25 2011-07-07 Ranbaxy Laboratories Limited Benzothiazoles and aza-analogues thereof use as antibacterial agents
EP2623101B1 (en) * 2009-04-02 2021-04-21 Merck Patent GmbH Piperidine and piperazine derivatives as autotaxin inhibitors
WO2011028492A2 (en) * 2009-08-24 2011-03-10 The Regents Of The University Of California Sortase a inhibitors
US20110120915A1 (en) * 2009-11-24 2011-05-26 Chevron U.S.A. Inc. Hydrogenation of solid carbonaceous materials using mixed catalysts
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
US20150174137A1 (en) * 2010-06-02 2015-06-25 Alcon Research, Ltd. Compositions for treating microbial infections
JP6085829B2 (ja) 2011-01-14 2017-03-01 スペロ トリネム， インコーポレイテッド ピリミジンジャイレースおよびトポイソメラーゼｉｖ阻害剤
PT2663556E (pt) 2011-01-14 2014-11-27 Vertex Pharma Processo de fabrico de inibidores de girase e topoisomerase iv
EP2663558A1 (en) * 2011-01-14 2013-11-20 Vertex Pharmaceuticals Incorporated Solid forms of gyrase inhibitor (r)-1-ethyl-3-[5-[2-{1-hydroxy-1-methyl-ethyl}pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl}-1h-benzimidazol-2-yl]urea
RU2625305C2 (ru) * 2011-01-14 2017-07-13 Сперо Тринем, Инк. Твердые формы ингибитора гиразы (r)-1-этил-3-[6-фтор-5[2-(1-гидрокси-1-метил-этил) пиримидин-5-ил]-7-(тетрагидрофуран-2-ил)-1н-бензимидазол-2-ил] мочевины
WO2012177707A1 (en) 2011-06-20 2012-12-27 Vertex Pharmaceuticals Incorporated Phosphate esters of gyrase and topoisomerase inhibitors
WO2014014845A1 (en) 2012-07-18 2014-01-23 Vertex Pharmaceuticals Incorporated Combination therapy comprising|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium|diseases
US9018216B2 (en) 2012-07-18 2015-04-28 Vertex Pharmaceuticals Incorporated Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2015004533A2 (en) 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
SG11201510409QA (en) * 2013-06-21 2016-01-28 Zenith Epigenetics Corp Novel bicyclic bromodomain inhibitors
AU2014298051B2 (en) 2013-07-31 2018-11-15 Zenith Epigenetics Ltd. Novel quinazolinones as bromodomain inhibitors
EP3102203A2 (en) 2014-02-03 2016-12-14 Spero Gyrase, Inc. Antibacterial combinations comprising polymyxin
EP2913330A1 (en) * 2014-02-27 2015-09-02 Laboratoire Biodim Condensed derivatives of imidazole useful as pharmaceuticals
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
WO2016087936A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridinones as bromodomain inhibitors
CN107207474B (zh) 2014-12-11 2021-05-07 恒翼生物医药科技(上海)有限公司 被取代的杂环作为溴结构域抑制剂
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
CN105884752B (zh) * 2015-02-13 2018-08-31 山东轩竹医药科技有限公司 并环类回旋酶和拓扑异构酶iv抑制剂
US10562886B2 (en) 2015-05-21 2020-02-18 The Regents Of The University Of California Anti-cancer compounds
CN106167486B (zh) * 2015-05-22 2019-06-14 北京四环制药有限公司 单环类回旋酶和拓扑异构酶iv抑制剂
EP4074378A1 (en) 2015-07-02 2022-10-19 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
EA201990043A1 (ru) 2016-06-16 2019-05-31 Янссен Сайенсиз Айрлэнд Анлимитед Компани Антибактериальные соединения
WO2017223516A1 (en) 2016-06-24 2017-12-28 The Regents Of The University Of California Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
EP4417262A3 (en) 2017-03-01 2024-11-27 Janssen Sciences Ireland Unlimited Company Combination therapy
US20210070747A1 (en) 2017-03-24 2021-03-11 Taisho Pharmaceutical Co., Ltd. 2(1h)-quinolinone derivative
CN110801455B (zh) * 2019-11-12 2020-06-02 河北医科大学第二医院 用于治疗mrsa的药物组合物及其应用
EP4077310B1 (en) * 2019-12-19 2024-05-01 Université de Strasbourg Sigma-1 receptor ligands and uses thereof
KR102919045B1 (ko) * 2022-06-09 2026-01-29 한국화학연구원 벤즈이미다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 또는 감염증의 예방 또는 치료용 약학적 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2015676A1 (de) * 1970-04-02 1971-10-21 Farbenfabriken Bayer Ag, 5090 Leverkusen Neue Imine der 2-Formyl-chinoxalindi-N-oxidcarbon-säure-(3) und deren Salze, Verfahren zu ihrer Herstellung und ihre Verwendung als antimikrobielle Mittel
US4174400A (en) * 1978-09-13 1979-11-13 Merck & Co., Inc. Anthelmintic benzimidazoles
US4512998A (en) * 1980-10-20 1985-04-23 Schering Corporation Anthelmintic benzimidazole carbamates
CA2028530A1 (en) 1989-11-21 1991-05-22 Christian Hubschwerlen Substituted pyrimidobenzimidazole derivatives
ATE155143T1 (de) * 1991-09-27 1997-07-15 Merrell Pharma Inc 2-substituierte indan-2-mercaptoacetylamid- verbindungen mit enkephalinase und ace- hemmwirkung
DE19514313A1 (de) 1994-08-03 1996-02-08 Bayer Ag Benzoxazolyl- und Benzothiazolyloxazolidinone
HRP960159A2 (en) 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
US5643935A (en) * 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
TW538046B (en) 1998-01-08 2003-06-21 Hoechst Marion Roussel Inc Aromatic amides having antiobiotic activities and the preparation processes, intermediates and pharmaceutical composition thereof
US6130235A (en) * 1998-05-22 2000-10-10 Scios Inc. Compounds and methods to treat cardiac failure and other disorders
AUPP873799A0 (en) 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
GB9911594D0 (en) 1999-05-19 1999-07-21 Smithkline Beecham Plc Novel compounds
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
MY138797A (en) 2000-12-15 2009-07-31 Vertex Pharma Bacterial gyrase inhibitors and uses thereof
MXPA04012628A (es) 2002-06-13 2005-03-23 Patricia Olivershaffer DERIVADOS Y COMPUESTOS RELACIONADOS DEL áCIDO 2-UREIDO-6-HETEROARIL-3H-BENZOIMIDAZOL-4-CARBOXILICO COMO INHIBIDORES DE GIRASA Y/O TOPOISOMERASA IV PARA EL TRATAMIENTO DE INFECCIONES BACTERIALES.
US8193352B2 (en) * 2003-01-31 2012-06-05 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7569591B2 (en) 2003-01-31 2009-08-04 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7618974B2 (en) 2003-01-31 2009-11-17 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
AR042956A1 (es) * 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
US7582641B2 (en) * 2003-01-31 2009-09-01 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US8394803B2 (en) 2005-11-07 2013-03-12 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof

Also Published As

Publication number Publication date
JP4691033B2 (ja) 2011-06-01
AU2004261545A1 (en) 2005-02-10
IL169720A (en) 2011-08-31
RU2350612C2 (ru) 2009-03-27
KR20060056270A (ko) 2006-05-24
JP2011046745A (ja) 2011-03-10
DK1592686T3 (da) 2009-10-19
TW200503708A (en) 2005-02-01
CN100393714C (zh) 2008-06-11
WO2005012292A1 (en) 2005-02-10
DE602004021904D1 (de) 2009-08-20
US8188095B2 (en) 2012-05-29
US20040235886A1 (en) 2004-11-25
RU2005127328A (ru) 2006-02-10
JP2006528677A (ja) 2006-12-21
ATE435859T1 (de) 2009-07-15
CY1109385T1 (el) 2014-07-02
US20130023525A1 (en) 2013-01-24
AU2004261545B2 (en) 2010-06-24
CA2513463A1 (en) 2005-02-10
ES2327642T3 (es) 2009-11-02
NO20053845L (no) 2005-08-16
ZA200505773B (en) 2006-09-27
AR042956A1 (es) 2005-07-13
MY139124A (en) 2009-08-28
PT1592686E (pt) 2009-08-25
CN1745077A (zh) 2006-03-08
US20090176771A1 (en) 2009-07-09
EP1592686B1 (en) 2009-07-08
EP1592686A1 (en) 2005-11-09
HK1087699A1 (zh) 2006-10-20
NZ541885A (en) 2009-01-31
CA2513463C (en) 2012-07-10
US7495014B2 (en) 2009-02-24
SI1592686T1 (sl) 2009-12-31
TWI334416B (en) 2010-12-11

Similar Documents

Publication Publication Date Title
MY139124A (en) Gyrase inhibitors and uses thereof
ZA200701629B (en) Gyrase inhibitors and uses thereof
PL374191A1 (en) 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections
AP2003002824A0 (en) Gyrase inhibitors and uses thereof
UA94901C2 (ru) Антибактериальные производные пиперидина
TNSN06071A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
WO2003010138A3 (en) Piperidine derivatives as antibacterial agents
TNSN07240A1 (en) Compounds for flaviviridae treatment
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
MY138285A (en) Fab i inhibitors
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
DE602004012269D1 (de) Quervernetzte glycopeptid-cephalosporin-antibiotika
NZ510369A (en) Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
TW200734344A (en) Antibacterial agents
MXPA05009712A (es) Composiciones que comprenden acido hialuronico para la prevencion de infecciones urogenitales.
DE602004024393D1 (de) Quervernetzte glycopeptid-cephalosporin-antibiotika
DK1434779T3 (da) Tværbundne glycopeptid-cephalosporinantibiotika
TW200630367A (en) Substituted adenines and the uses thereof
WO2006120563A3 (en) Antibacterial agents
ATE335739T1 (de) Cak inhibitoren und deren verwendungen
MXPA03005374A (es) Carbazoles antitumorales.
DE60326710D1 (de) Trizyklische antibakterielle makrolidderivate
TW200621740A (en) Compound for treating hepatitis B and composition thereof
WO2003068790A3 (en) Macrolide antibacterial compounds

Legal Events

Date Code Title Description
FG Grant or registration